9FD-26161-47982
4 vaccinations
4 coded responses
53 check-ins
3 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 000
- Registered
- 2020-12-22
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-22
Registered in v-safe
-
2020-12-22
Dose 1 — Pfizer-BioNTech
- 2020-12-22
- 2020-12-23
- 2020-12-24
- 2020-12-25
- 2020-12-26
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2021-01-05
-
2021-01-12
Dose 2 — Pfizer-BioNTech
- 2021-01-12
-
2021-01-13
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-19
- 2021-01-26
- 2021-02-02
- 2021-02-09
- 2021-02-16
- 2021-02-23
- 2021-04-13
- 2021-07-15
-
2021-09-30
Dose 3 — Pfizer-BioNTech
- 2021-09-30
- 2021-10-01
- 2021-10-02
- 2021-10-03
- 2021-10-04
- 2021-10-05
- 2021-10-06
- 2021-10-07
-
2021-10-14
Survey response — day 14, dose 3MedDRA: Migraine — Feeling: Good · Be unable to do your normal daily activitiesFree text: MigraineMedDRA releases: 2024-11 · check-in free text available
- 2021-10-21
- 2021-10-28
- 2021-11-04
- 2021-11-11
- 2021-12-30
-
2022-03-31
Survey response — 6 months, dose 3MedDRA: Cough, Nasopharyngitis — Feeling: Poor · Be unable to do your normal daily activitiesFree text: Cold/coughMedDRA releases: 2024-11 · check-in free text available
-
2022-10-02
Survey response — 12 months, dose 3MedDRA: Nasopharyngitis — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Several coldsMedDRA releases: 2024-11 · check-in free text available
-
2022-12-12
Dose 4 — Pfizer-BioNTech
- 2022-12-13
- 2022-12-14
- 2022-12-15
- 2022-12-16
- 2022-12-17
- 2022-12-18
- 2022-12-19
- 2022-12-26
- 2023-01-02
-
2023-01-09
Survey response — day 28, dose 4MedDRA: Migraine, Pre-existing disease — Feeling: Fair · Be unable to do your normal daily activitiesMedDRA releases: 2024-11
- 2023-01-16
- 2023-01-25
- 2023-03-13
- 2023-06-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-22 | Pfizer-BioNTech | |
| 2 | 2021-01-12 | Pfizer-BioNTech | |
| 3 | 2021-09-30 | Pfizer-BioNTech | No |
| 4 | 2022-12-12 | Pfizer-BioNTech | No |
Free text
Release 10 — day 14, dose 3
Symptoms: Migraine
Release 11 — 6 months, dose 3
Symptoms: Cold/cough
Release 12 — 12 months, dose 3
Symptoms: Several colds
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Migraine | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release